MarketCapExport financials
Dynavax Technologies Corporation (DVAX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Dynavax Technologies Corporation Financial Statements 2024-2008 | DVAX
Annual Financial Statements Dynavax Technologies Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.73 B | 1.61 B | 1.36 B | 1.51 B | 636 M | 359 M | 687 M | 863 M | 148 M | 792 M | 450 M | 345 M | 515 M | 443 M | - | - | - |
Shares |
130 M | 129 M | 126 M | 116 M | 101 M | 72 M | 62.4 M | 52.6 M | 38.5 M | 32.9 M | 26.3 M | 19.6 M | 17 M | 12.5 M | 82.5 M | - | - |
Historical Prices |
13.3 | 12.5 | 10.8 | 13 | 6.31 | 5.05 | 11 | 16.1 | 4.1 | 24.1 | 17.1 | 17.4 | 30.9 | 34.8 | - | - | - |
Net Income |
27.3 M | -6.39 M | 293 M | 76.7 M | -75.2 M | -153 M | -159 M | -95.2 M | -112 M | -107 M | -90.7 M | -66.7 M | -69.9 M | -48.6 M | -57.3 M | -30.6 M | - |
Revenue |
277 M | 232 M | 723 M | 439 M | 46.6 M | 35.2 M | 8.2 M | 327 K | 11 M | 4.05 M | 11 M | 11.3 M | 9.71 M | 21.6 M | 24 M | 40.3 M | - |
Cost of Revenue |
49.4 M | 50.2 M | 262 M | 174 M | 11.4 M | 10.2 M | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 15.8 M | -13.6 M | - | - | 4.05 M | 11 M | 11.3 M | 9.71 M | 21.6 M | - | - | - |
Operating Income |
-4.12 M | -37 M | 284 M | 134 M | -68.4 M | -135 M | -153 M | -96 M | -111 M | -105 M | -91.3 M | -66.5 M | -67.6 M | -47.6 M | -47.6 M | -15.1 M | - |
Interest Expense |
293 K | -152 K | 111 K | 11.2 M | 19.1 M | 17 M | 9.34 M | -486 K | -2.49 M | 572 K | 35 K | -348 K | 2.35 M | 1.96 M | 1.65 M | 124 K | - |
EBITDA |
505 K | -32.7 M | 287 M | 139 M | -64.1 M | -100 M | -139 M | -92 M | -108 M | -104 M | -89.9 M | -65.2 M | -66.4 M | -47.3 M | -46.2 M | -13.3 M | - |
Operating Expenses |
- | - | - | - | - | 137 M | 140 M | 93.5 M | 122 M | 109 M | 102 M | 77.7 M | 77.3 M | 69.2 M | - | - | - |
General and Administrative Expenses |
170 M | 153 M | 131 M | 100 M | 79.3 M | 75 M | 64.8 M | 27.4 M | 37.3 M | 22.2 M | 17.8 M | 26.9 M | 28.2 M | 17.6 M | 16.9 M | 15.7 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Dynavax Technologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
117 M | 119 M | 125 M | 125 M | 131 M | 131 M | 130 M | 130 M | 129 M | 129 M | 128 M | 128 M | 127 M | 126 M | 125 M | 123 M | 117 M | 115 M | 112 M | 110 M | 110 M | 97.3 M | 85.5 M | 83.9 M | 75.1 M | 65.1 M | 63.8 M | 62.7 M | 62.6 M | 62.3 M | 61.7 M | 61 M | 57.6 M | 49.7 M | 41.8 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 38.4 M | 36.5 M | 29.3 M | 27.1 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 23.6 M | 183 M | 183 M | 183 M | 181 M | 178 M | 168 M | 155 M | 142 M | 124 M | 118 M | 116 M |
Net Income |
26.9 M | 18.7 M | -96.1 M | - | 17.6 M | 11.4 M | -8.72 M | - | 14.3 M | 3.43 M | -24.3 M | - | 63.8 M | 129 M | 32.9 M | - | -28.4 M | 4.47 M | 891 K | - | 4.4 M | -51.6 M | -12.6 M | -36.8 M | -33.5 M | -42.7 M | -39.7 M | -40 M | -40.5 M | -39.4 M | -39 M | -27.4 M | -22.1 M | -20.3 M | -25.3 M | -21.7 M | -34.7 M | -29 M | -27 M | -26.9 M | -30.1 M | -23.6 M | -26.2 M | -22.3 M | -29.8 M | -24.8 M | -13.8 M | -13.1 M | -15.7 M | -17.2 M | -20.8 M | -20.5 M | -17.8 M | -15.1 M | -16.5 M | -4.27 M | -15.2 M | -10.6 M | -18.5 M |
Revenue |
94.9 M | 95.4 M | 68.2 M | - | 80.6 M | 73.8 M | 50.8 M | - | 69.5 M | 60.2 M | 46.9 M | - | 168 M | 256 M | 114 M | - | 108 M | 52.8 M | 83.3 M | - | 13.4 M | 2.67 M | 10.9 M | 10.6 M | 10.6 M | 8.3 M | 5.77 M | 5.32 M | 1.46 M | 1.25 M | 165 K | 21 K | 53 K | 105 K | 148 K | 7.29 M | 162 K | 2.65 M | 942 K | 685 K | 1.19 M | 1.55 M | 627 K | 2.28 M | 2.21 M | 3.05 M | 3.5 M | 2.85 M | 2.93 M | 3.39 M | 2.08 M | 1.81 M | 2.87 M | 2.68 M | 2.35 M | 11.4 M | 1.17 M | 7.27 M | 1.74 M |
Cost of Revenue |
14.4 M | 14 M | 13.8 M | - | 13.1 M | 12 M | 11 M | - | 13.2 M | 13.5 M | 14.7 M | - | 61.3 M | 83.4 M | 40 M | - | 60.1 M | - | 24.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
21.3 M | 14.4 M | -23.6 M | - | 10.1 M | 5.2 M | -17.8 M | - | 5.12 M | -3.4 M | -30.2 M | - | 61.4 M | 128 M | 30.8 M | - | 16.1 M | 9.17 M | 28.5 M | - | -13.8 M | -23.3 M | -19.3 M | - | -30.6 M | -39 M | -37.9 M | - | -38.9 M | -38.1 M | -38.3 M | - | -22.4 M | -20.3 M | -25.5 M | - | -34.8 M | -29.3 M | -27.3 M | - | -28.4 M | -23.2 M | -26.5 M | - | -30.1 M | -24.9 M | -14 M | - | -15.6 M | -17 M | -20.9 M | - | -17.1 M | -14.6 M | -15.8 M | - | -14.8 M | -10.1 M | -17.9 M |
Interest Expense |
-27 K | -596 K | -423 K | - | -152 K | 1.7 M | 101 K | - | 266 K | 1.69 M | 1.69 M | - | 1.68 M | 1.68 M | 1.68 M | - | 1.68 M | 3.11 M | 4.71 M | - | 4.79 M | 4.73 M | 4.73 M | - | 4.78 M | 4.6 M | 2.73 M | - | 2.74 M | 2.69 M | 1.16 M | - | -166 K | -232 K | 20 K | - | -26 K | 48 K | 46 K | - | 62 K | 263 K | 247 K | - | 216 K | 22 K | 62 K | - | 24 K | 27 K | 32 K | - | 589 K | 589 K | 587 K | - | 485 K | 487 K | 490 K |
EBITDA |
25 M | 16.8 M | -22.5 M | - | - | - | -16.6 M | - | - | - | -29.2 M | - | 64.4 M | 128 M | 31.7 M | - | 19.3 M | 9.17 M | 29.6 M | - | -10.7 M | -21.3 M | -18.3 M | - | -22.8 M | -35.8 M | -36.2 M | - | -36.4 M | -36.5 M | -37.5 M | - | -19.9 M | -18.6 M | -24.7 M | - | -33.3 M | -28.3 M | -26.9 M | - | -27.5 M | -22.6 M | -26.1 M | - | -29.1 M | -24.2 M | -13.6 M | - | -14.6 M | -16.4 M | -20.6 M | - | -16.2 M | -14.1 M | -15.6 M | - | -13.8 M | -9.39 M | -17.6 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.3 M | 43.6 M | - | 40.4 M | 39.4 M | 38.5 M | - | 22.4 M | 20.4 M | 25.6 M | - | 35 M | 31.9 M | 28.2 M | - | 29.6 M | 24.8 M | 27.1 M | - | 32.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
40.1 M | 50.4 M | 47.7 M | - | 43.1 M | 41.7 M | 44.1 M | - | 38.1 M | 37.1 M | 36.5 M | - | 32 M | 36.2 M | 32.2 M | - | 26.9 M | 21.6 M | 22.4 M | - | 21.5 M | 19 M | 20.9 M | - | 18.5 M | 17.9 M | 18.3 M | - | 15.8 M | 15.7 M | 16.9 M | - | 6.03 M | 5.61 M | 6.47 M | - | 11.8 M | 9.15 M | 8.17 M | - | 5.52 M | 5.1 M | 4.86 M | - | 4.08 M | 4.08 M | 4.16 M | - | 5.81 M | 7.64 M | 8.8 M | - | 7.12 M | 5.96 M | 5.79 M | - | 4.22 M | 4.05 M | 4.75 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Main types of financial statements Dynavax Technologies Corporation DVAXFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Dynavax Technologies Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Kymera Therapeutics
KYMR
|
$ 112.63 | -0.73 % | $ 9.52 B |  USA |
 |
Praxis Precision Medicines
PRAX
|
$ 256.47 | -3.03 % | $ 5.77 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.37 | -0.72 % | $ 144 M |  Niderland |
 |
PTC Therapeutics
PTCT
|
$ 62.62 | -0.48 % | $ 4.98 B | USA |
 |
Arcus Biosciences
RCUS
|
$ 19.1 | -19.58 % | $ 2.05 B | USA |
 |
Larimar Therapeutics
LRMR
|
$ 2.42 | -0.82 % | $ 201 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
$ 805.67 | -0.22 % | $ 84.3 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
$ 3.01 | -0.33 % | $ 127 M | USA |
 |
Rafael Holdings
RFL
|
$ 1.3 | 0.78 % | $ 38.2 M | USA |
 |
REGENXBIO
RGNX
|
$ 7.17 | -3.11 % | $ 370 M | USA |
 |
Royalty Pharma plc
RPRX
|
$ 62.15 | -0.16 % | $ 26.7 B | USA |
 |
Seer
SEER
|
$ 2.03 | 2.53 % | $ 112 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.24 | 29.1 % | $ 57.5 M | USA |
 |
Zymeworks
ZYME
|
$ 28.12 | 4.48 % | $ 1.45 B |  Canada |
 |
SIGA Technologies
SIGA
|
$ 3.12 | -0.95 % | $ 223 M | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 25.83 | 7.0 % | $ 1.24 T |  France |
 |
22nd Century Group
XXII
|
$ 0.27 | 2.13 % | $ 49.7 K | USA |
 |
Syndax Pharmaceuticals
SNDX
|
$ 13.15 | -0.75 % | $ 1.14 B | USA |
 |
Soligenix
SNGX
|
$ 0.35 | -1.27 % | $ 1.82 M | USA |
 |
Intellia Therapeutics
NTLA
|
$ 11.65 | -1.6 % | $ 1.26 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.85 | 1.89 % | $ 1.66 B | USA |
 |
Sarepta Therapeutics
SRPT
|
$ 18.56 | -3.18 % | $ 1.86 B | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.76 | 1.73 % | $ 2.3 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
$ 0.46 | -10.31 % | $ 5.67 B |  Israel |
 |
SELLAS Life Sciences Group
SLS
|
$ 12.14 | 1.34 % | $ 1.32 B | USA |
|
Protara Therapeutics
TARA
|
$ 2.5 | -2.34 % | $ 107 M | USA |
 |
Relay Therapeutics
RLAY
|
$ 18.41 | -0.22 % | $ 3.16 B | USA |
 |
Pfizer
PFE
|
$ 29.85 | -0.95 % | $ 170 B | USA |
 |
Supernus Pharmaceuticals
SUPN
|
$ 41.21 | -0.05 % | $ 2.33 B | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
$ 19.93 | -0.75 % | $ 31.5 B |  Japan |
 |
Revolution Medicines
RVMD
|
$ 194.28 | -1.15 % | $ 36.9 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
$ 88.62 | -1.75 % | $ 5.76 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.65 | 3.4 % | $ 281 M | USA |
 |
Sana Biotechnology
SANA
|
$ 2.35 | -0.42 % | $ 595 M | USA |
 |
Zai Lab Limited
ZLAB
|
$ 24.2 | -3.51 % | $ 26.5 B |  China |
 |
Pulmatrix
PULM
|
$ 1.57 | 9.79 % | $ 5.73 B | USA |
 |
Zentalis Pharmaceuticals
ZNTL
|
$ 2.36 | -1.26 % | $ 170 M | USA |
 |
Zoetis
ZTS
|
$ 79.62 | -0.52 % | $ 35.3 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 15.92 | -0.62 % | $ 1.57 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.87 | -3.61 % | $ 1.26 B | Israel |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | USA |
 |
AC Immune SA
ACIU
|
$ 2.47 | -0.8 % | $ 249 M |  Schweiz |
 |
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | USA |
 |
Adagene
ADAG
|
$ 2.41 | -3.6 % | $ 142 M | China |
 |
Adial Pharmaceuticals
ADIL
|
$ 4.11 | 7.59 % | $ 2.75 M | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.5 | -1.32 % | $ 191 M | Schweiz |
 |
ADMA Biologics
ADMA
|
$ 11.01 | -1.96 % | $ 2.62 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 20.46 | -3.45 % | $ 229 M | USA |
 |
Allogene Therapeutics
ALLO
|
$ 1.33 | -0.38 % | $ 293 M | USA |
 |
Amgen
AMGN
|
$ 438.34 | -0.14 % | $ 236 B | USA |